Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9678618 | 0.77 | KCNN4 (0.32) | — | |
| SCHEMBL22991339 | 0.72 | TSHR (0.36) | — | |
| SCHEMBL21189690 | 0.68 | TSHR (0.36) | — | |
| SCHEMBL17419438 | 0.68 | — | — | |
| SCHEMBL21189688 | 0.66 | KCNN4 (0.39) | — | |
| SCHEMBL28565820 | 0.62 | KCNN4 (0.45) | — | |
| SCHEMBL22737598 | 0.62 | ESR1 (0.39) | — | |
| SCHEMBL28447796 | 0.61 | KCNN4 (0.39) | — | |
| SCHEMBL27810950 | 0.61 | KCNN4 (0.39) | — | |
| SCHEMBL21189641 | 0.60 | KIF11 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176948-A1 | Building block capable of functional entity transfer to nucleophil | NUEVOLUTION A/S (DK) | 2005-08-11 | — | — | US | disclosed |
| EP-1487851-A2 | A BUILDING BLOCK CAPABLE OF FUNCTIONAL ENTITY TRANSFER TO NUCLEOPHIL | Nuevolution A/S (DK) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003078627-A2 | A BUILDING BLOCK CAPABLE OF FUNCTIONAL ENTITY TRANSFER TO NUCLEOPHIL | NUEVOLUTION A/S (DK) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176948-A1 | Building block capable of functional entity transfer to nucleophil | DNTT, NME2, SLC29A2 | TRPV4 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.